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TRIVALENT chromium has been identified as an essential trace element in the
maintenance of normal carbohydrate metabolism, both in man and in animals. Its
deficiency leads to an impairment of glucose tolerance which is reversed when the
diet is supplemented by chromium salts, and more rapidly by foods with a high
organic content.'
The absorption of chromium depends upon the chemical form in which it is
present. The active principle 'glucose tolerance factor' (GTF) is present in a variety
of foods including liver, meat, cheese and whole grain. GTF fulfils the criteria ofan
essential micronutrient more closely than simple chromium salts. Its gross
composition appears to be a complex with niacin and amino acids. The richest
known source is brewers yeast but the synthesis of pure GTF has not yet been
completely successful. GTF is rapidly absorbed and biologically active chromium
potentiates the action of insulin on the peripheral receptor sites.2
Inorganic chromium salts have been used in the treatment ofhuman diabetics and
good results have been reported in some, but not all, instances. More recently
administration of GTF in the form of brewers yeast has been tried with some
success. The subject still remains in the exploratory stage, with a lack of controlled
studies and of a pure active complex for chemical testing. The present hypothesis is
that impaired glucose tolerance in good responders may be related to insulin
resistance associated with nutritional chromium deficiency.3
In view of the increasing interest in this subject and the apparent importance of
geographical location, we felt a short preliminary double blind cross over study with
brewers yeast and a placebo might be helpful before setting up a more extensive
trial. We limited the sample toType 2 diabetics who might reasonably beexpected to
have insulin resistance rather than an absolute deficiency. In addition to standard
parameters of diabetic control which have been the subject of previous reports,
(fasting blood glucose, the glucose tolerance test and the serum cholesterol and
triglyceride levels), we were particularly interested to see if any beneficial effect
might occur in the levels of glycosylated haemoglobin (Hb Aic) and high density
lipoprotein (HDL).
METHODS
Thirty seven non insulin-dependent diabetics (18 male/19 female) were studied as
outpatients. The mean age of the group was 64 + 1.6 years (mean ± S.E.M.),
duration of diabetes 7.0 1.0 years and the percentage ofideal body weight ranged
from 105 to 120 per cent. All the subjects were treated with diet and a sulphonylurea
derivative. Treatment was kept constant for three months prior to the trial and
throughout the trial itself.
110After informed consent had been obtained, patients entered the random-order
double blind cross over study. Thetrial consisted oftwo successive7-week treatment
periods during which existing treatment was supplemented with either brewers yeast
(as a source of GTF) or placebo. Two opaque capsules containing either 200 mg of
brewers yeast or a cellulose placebo were taken four times daily before meals. The
chromium content of the yeast was 0.8 ug/g so that during active treatment subjects
ingested an additional 1.28 ug of organic chromium daily.
Fasting blood was withdrawn from an antecubital vein prior to treatment and at
the end of each treatment period. Plasma glucose concentration was measured by a
glucose oxidase method on a Techicon Autoanalyser II.4 Percentage haemoglobin
Aic (Hb Alc) was determined by column chromatography.5 Serum cholesterol and
triglyceride were estimated using an automated enzymatic system.6 HDL
concentration was estimated after precipitation of LDL and VLDL with manganese
chloride,7 and the supernatent measured for cholesterol by the standard technique.
In addition, subjects underwent an oral glucose tolerance test 50 g load (OGTT),
before the trial and at the end of each treatment period. The area under the curve of
the OGTT was calculated by manual counting of squares.
The initial values and the values observed after the placebo and active treatment
periods are shown in Table I. The values observed after treatment were compared
with the initial values using analysis of variance. which was performed at the
Queen's University of Belfast Computing Centre.
TABLE I
Effect of1.6g brewers yeast (GTF) daily compared with placebo on blood glucose
HbAikandserum lipidsafter 7 weeks treatment.
HbAic%
Fasting blood glucose
(mmol/l)
Area under GTT
Triglyceride
(mmol/l)
Cholesterol
(mmol/l)
HDL
(mmol/l)
N Initial Placebo
37 8.0 7.5a 6.6b
(+0.3) (±0.3) (±0.2)
37 9.2 9.0 9.1
(±+ 0.5) (±+ 0.7) (±+ 0.7)
37 29.3 29.3 29.1
(±+ 1.4) (± 1.4) (±+ 1.3)
24 1.4 1.6 1.5
(+0.2) (+0.2) (+0.2)
26 5.7 5.8 5.7
(±0.2) (+0.2} (+0.2)
13 1.1 1.2 1.5c
(±0.1) (±+ 0.1) (±+ 0.1)
Results are given as mean and ( + SEM)
ap < 0.001 placebo v initial
bp < 0.001 GTF v placebo
cp < 0.05 GTF v placebo
Statistical significance by analysis of variance
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GTFRESULTS
Hb Aic levels reduced from 8.0 ± 0.3 per cent to 7.5 + 0.3 per cent during placebo
treatment (p < 0.001). Active treatment with GTP was associated with a fall in
Hb Aic to 6.6 ± 0.2 per cent which was significantly greater than that observed after
placebo treatment (p < 0.001).
All subjects improved in the first treatment period irrespective ofwhether this was
yeast or placebo. This could have been due to improved dietary compliance. In the
15 subjects who had placebo before yeast GTF Hb Aic levels fell from 7.91 + 0.42
per cent to 7.53 + 0.30 per cent during placebo treatment, and fell further to
6.28 + 0.31 per cent during active treatment. In the 22 subjects who received active
treatment before placebo Hb Aiclevels fell from 8.14 + 0.46 per cent to 6.91 + 0.35
per cent during active treatment but rose to 7.56 + 0.38 per cent during placebo
treatment. These results confirm an order-of-treatment effect but suggest that active
treatment can reduce Hb Aic levels.
In GTF v placebo comparison, active treatment with GTF was also associated
with an increase in HDL levels (p < 0.05).
Fasting plasma glucose levels, serum cholesterol, triglyceride levels and the area
under the curve of an OGTT were unchanged after placebo and active treatment
when compared with initial values.
DISCUSSION
The average daily intake of chromium has been estimated as approximately 60 ug
with a range of 5-150 ug, but only 1 per cent of the inorganic form is absorbed as
against 10-25 per cent ofbiologically active organic GTF. The minimal requirements
of the latter are estimated 10-30 ug.3 The body pool of chromium depends upon an
adequate background level. Where the water supply (the main source of inorganic
chromium) shows no detectable levels of chromium, tissue chromium levels are low
and carbohydrate tolerance impaired.8 The water supply source for Belfast contains
20 ug/l chromium; the European Economic Community standard is 50 ug/1. It is
possible that our subjects were relatively chromium depleted and would therefore be
expected to respond favourably to dietary chromium supplementation. Even though
poorly absorbed, inorganic chromium has produced beneficial effects after several
weeks to months in diabetics where there is reason to consider the body stores were
low.9 10,11,12 However, a double blind cross over study of inorganic chromium and
placebo in younger diabetics (ages 28-47) failed to show improvement in glucose
tolerance. II
Organic chromium complex in the form of brewers yeast has been shown to
improve glucose tolerance,'4'"5 but these studies included no placebo treatment
period for comparison. Large quantities of brewers yeast must be ingested daily to
ensure adequate amounts of GTF. Previous studies have used 5-10 g daily.'4' ' This
creates a problem of patient compliance, which is difficult to check as plasma
chromium levels are only slightly increased during chromium supplementation." In
an attempt to overcome these difficulties a single blind study in elderly subjects,
both normal and diabetic, compared the effect of 9 g of brewers yeast against
chromium poor torula yeast given in orange juice over an eight week period.'6
Glucose tolerance improved, insulin output decreased and cholesterol fell with
brewers yeast; unfortunately difficulties in assay precluded reliable data for
chromium studies.
112Our own investigation has also been limited byan inability to assess the chromium
status with accuracy. As yet chromium is a difficult element to determine
reliably'7' 18 and the spread of mean value reported for chromium in the serum is
very large 0.14 to 782 ng Cr ml. We were unable to obtain a brewers yeast with a
high chromium content and were advised a torula yeast might be toxic. A double
blind trial is limited by patients conforming and a dosage ofeight capsules daily was
considered as acceptable. Our studywith small amounts oforganic chromium over a
seven week period nevertheless suggested a beneficial effect on two important
parameters of diabetic control not previously reported on, namely the HDL and
Hb Aic levels. The discrepancy between the fall in Hb Aic values and the lack of
change in fasting blood glucose value requires comment. The correlation between
these two parameters of glucose control is accepted as approximately r=0.75 in
Type 2 diabetics.'9 Single fasting blood glucose estimates are subject to fluctuation
and depend on patient co-operation in the immediate period before the test, and
close supervision in this period as with inpatients might have given a more reliable
correlation. The Hb Aic results may therefore have been a better index of glucose
control under the outpatient conditions ofour trial. The correlation between Hb Aic
values and the oral glucose tolerance is accepted as poor and does not negate our
findings. The latter estimates the response to an artificial glucose load and the
former the average daily blood glucose level over a 4-6 week period.20
In spite ofits limitations the present study is confirmatory that organic chromium
may be ofvalue in Type 2 diabetes. Hb Aiclevels of 12.6 per cent and above may be
related to the microvascular complications of diabetes,21 and so a reduction in this
may improve the individual prognosis. It has also been suggested that chromium
deficiency may have a role in insulin resistance and sepsis.22 Chromium is still
worthy of attention and research. Many of the present difficulties will be resolved
when reliable and reproducible methods of chemical estimation become generally
available, and the effects ofmore concentrated forms oforganic chromium or GTF
are subjected to clinical trials.
SUMMARY
Fasting blood glucose, theintegrated areaunder a two hour 50 g glucose tolerance
test, and Hb Aic were measured in 37 Type 2 (non insulin-dependent) diabetics with
maturity onset. Subjects were out-patients on diet and sulphonylurea therapy which
remained unchanged. Estimations of serum cholesterol, triglyceride and HDL were
completed in a proportion ofpatients. A double blind cross over study compared a
placebo with glucose tolerance factor in the form ofbrewers yeast supplementation
containing 1.28 ug chromium daily over a 7 week trial period. Treatment with
brewers yeast (GTF) improved diabetic control as demonstrated by a fall in Hb Aic
per cent (P < 0.001) and a rise in HDL (P < 0.05). The local water supply is low in
chromium at 20 ug per litre.
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